Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunic, Inc.

1.15
+0.03002.68%
Post-market: 1.13-0.0200-1.74%17:13 EDT
Volume:534.22K
Turnover:608.67K
Market Cap:103.59M
PE:-1.02
High:1.17
Open:1.12
Low:1.10
Close:1.12
Loading ...

Immunic to Participate in Scientific and Investor Conferences in March

PR Newswire
·
03 Mar

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
26 Feb

Eqs-News: Immunic Presents Key Vidofludimus Calcium Data at the Actrims Forum 2025, Highlighting Its Potential in Multiple Sclerosis

THOMSON REUTERS
·
26 Feb

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

PR Newswire
·
26 Feb

B.Riley Financial Sticks to Their Buy Rating for Immunic (IMUX)

TIPRANKS
·
24 Feb

Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week

Simply Wall St.
·
22 Feb

Immunic Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Feb

Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and Immunic (IMUX)

TIPRANKS
·
21 Feb

BRIEF-Immunic's Oral Imu-856 Demonstrated Dose-Dependent Increase Of Glp-1

Reuters
·
20 Feb

Immunic: Dose-Dependent Increase of Endogenous Glp-1 Levels Observed in Post Hoc Analysis of Patients From Phase 1B Clinical Trial in Celiac Disease

THOMSON REUTERS
·
20 Feb

Immunic Inc: Dose-Dependent Reduction of Body Weight Gain and Food Consumption Observed in Preclinical Study

THOMSON REUTERS
·
20 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
20 Feb

Immunic Inc expected to post a loss of 23 cents a share - Earnings Preview

Reuters
·
18 Feb

Immunic to Participate in Investor and Scientific Conferences in February

PR Newswire
·
04 Feb

Promising Outlook for Immunic’s VidoCa in PMS: Favorable Risk/Reward and Key Metrics Drive Buy Rating

TIPRANKS
·
28 Jan

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
07 Jan